Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Cancer and Leukemia Group B
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen, consisting of paclitaxel, carboplatin, and fluorouracil (5-FU), is utilized as a neoadjuvant (preoperative) treatment in conjunction with radiation therapy for patients with locally advanced esophageal and gastroesophageal junction (GEJ) cancers. The regimen was evaluated in clinical trials conducted by the Alliance for Clinical Trials in Oncology. Paclitaxel acts as a microtubule stabilizer by binding to tubulin, carboplatin functions as a DNA-damaging platinum agent that induces cross-linking, and fluorouracil serves as an antimetabolite that inhibits thymidylate synthase. Together, these agents work synergistically to reduce tumor burden and improve the feasibility of surgical resection (esophagectomy).
- Brand names
- TaxolParaplatinAdrucil
- Other names
- Paclitaxel/Carboplatin/5-FUPCF regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on paclitaxel + carboplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + fluorouracil.